https://www.thebodypro.com/collection/2018-90-90-90-targets-workshop

Featured

Medicines Patent Pool Model May Expand Beyond HIV Medications Img

Medicines Patent Pool Model May Expand Beyond HIV Medications

The Medicines Patent Pool, which negotiates licenses with the manufacturers of new drugs that allow other companies to produce generic versions for distribution in low- and middle-income countries, is looking to expand beyond HIV drugs to medications...

Public Health Approach = Do the Best for the Most People Using Resources Efficiently Img

Public Health Approach = Do the Best for the Most People Using Resources Efficiently

While almost 60% of people living with HIV globally are on treatment, the numbers for new seroconversions averted and HIV-related deaths are no longer improving.

European continent marked with flags
News

HIV Stigma Still Common in Europe, Survey Finds

In a recent survey of people not living with HIV, many still believed that people living with HIV should not be allowed to work in hospitals, restaurants, or universities, among other occupations, and 68% said they would be uncomfortable dating someo...

Adult HIV Prevalence and Estimated Number of Adults and Children Infected With HIV, 2016
Children (Ages 0-17)

HIV Prevention and Treatment Strategies for Africa's Growing Teen and Young Adults Are Central to Future World Progress

For the world's HIV epidemics to be controlled, effective community-based prevention programs reaching adolescents and young people, especially in sub-Saharan Africa, need to be developed, funded, and scaled up.

David Barr

HIV Activist David Barr on Going Beyond 90-90-90

Barr, a longtime AIDS activist and co-founder of Treatment Action Group (TAG), was the coordinator for the Joep Lange Institute's AIDS 2018 preconference workshop, Meeting the 90-90-90 Targets: Faster and Better.

Anton Pozniak at the 90-90-90 Targets Workshop
News

How Will Long-Acting HIV Antiretrovirals Work in the Real World?

Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.